Quick Summary
- Retatrutide is a triple agonist peptide (GLP-1, GIP, Glucagon) under active clinical investigation.
- Preclinical and Phase II trial data show dose-dependent fat loss, metabolic, and appetite-regulation effects.
- Titration protocols start at 1mg/week and escalate gradually — skipping steps increases adverse event risk.
- Peptides Lab UK offers HPLC-verified, COA-confirmed Retatrutide in lyophilised vials for research purposes only.
What Is Retatrutide and Why Dosage Matters
Retatrutide is a powerful investigational peptide designed to activate three hormonal receptors simultaneously. This multi-receptor approach impacts appetite, metabolism, insulin response, and fat oxidation in ways that single or dual agonists cannot replicate.
Because of its potency and long-acting half-life (~6 days), most preclinical protocols follow a titrated dosage approach — gradually increasing the dose over several weeks to reduce adverse reactions and allow receptor adaptation.
Source: Jastreboff et al., NEJM, June 2023 — Phase II Retatrutide Trial
Retatrutide Dosage Chart (Based on Phase II Trial Protocol)
| Week | Dose (mg/week) | Notes |
|---|---|---|
| 1–4 | 1.0 mg | Starting dose — receptor sensitisation phase |
| 5–8 | 4.0 mg | Appetite suppression becomes measurable |
| 9–12 | 8.0 mg | Visceral fat reduction, improved insulin sensitivity |
| 13+ | 12.0 mg | Maximum dose used in Phase II — 24.2% mean weight reduction at 48 weeks |
Note: Some preclinical protocols use intermediate doses (2.5mg, 5mg, 7.5mg, 10mg). The Phase II trial used 1mg → 4mg → 8mg → 12mg escalation at 4-week intervals.
Titration Guide: Best Practices
To replicate the safety-first model used in Phase II studies:
- Start at 1mg/week regardless of the research model’s starting weight
- Hold each dose for at least 4 weeks before escalating
- Monitor body composition and metabolic markers at each stage before adjusting
- Do not attempt dose compression — glucagon receptor activation at high starting doses produces disproportionate adverse responses
⚠️ Note: Retatrutide is a research peptide and not approved for human use. All dosage information is for research reference only.
How to Reconstitute Retatrutide for Research
Standard supply format: 20mg lyophilised vial. The following reconstitution protocol is standard for research applications:
- Allow vial to reach room temperature before opening (prevents condensation entering the vial)
- Draw 2ml of bacteriostatic water into a sterile syringe
- Inject the water slowly down the side of the vial — do not inject directly onto the lyophilised powder as this can denature the peptide
- Gently swirl (do not shake) until the powder is fully dissolved — this produces a 10mg/ml solution
- At this concentration: 0.1ml = 1mg
- Refrigerate at 2–8°C. Use within 28 days. Do not freeze once reconstituted.
Dose volumes at 10mg/ml: 1mg = 0.10ml | 4mg = 0.40ml | 8mg = 0.80ml | 12mg = 1.20ml
Retatrutide Research Outcomes by Dose Level
- 1–4mg: Appetite modulation, mild weight effects in early-phase models
- 8mg: Significant visceral fat reduction, improved fasting glucose, measurable thermogenic response
- 12mg: Maximum studied — 24.2% mean body weight reduction at 48 weeks (NEJM, 2023). Near-maximal fat loss; pronounced lipolysis and energy expenditure increase.
This dose-dependent response is consistent with other GLP-1 family agonists, but Retatrutide’s glucagon activity produces thermogenesis not observed with Tirzepatide or Semaglutide at equivalent doses.
Supporting Data: PubMed — Retatrutide Phase II Mechanisms (PMID: 37369579)
Frequently Asked Questions
What is the correct starting dose for Retatrutide in research?
The Phase II trial protocol used 1mg per week as the starting dose, held for 4 weeks before the first escalation. This starting point applies regardless of the research model’s body weight — the rationale is receptor sensitisation, not dose-per-kg calculation.
How often is Retatrutide dosed?
Retatrutide has an approximately 6-day half-life and is dosed once weekly in all published research protocols. More frequent dosing does not appear in the literature and would produce accumulation above intended levels.
What is the maximum dose used in human trials?
12mg per week was the highest dose studied in the NEJM Phase II trial. This produced 24.2% mean body weight reduction at 48 weeks. Higher doses have not been reported in peer-reviewed literature.
Why does reconstitution method matter for Retatrutide?
Retatrutide is a 39-amino-acid peptide and relatively fragile compared to smaller research peptides. Injecting reconstitution solvent directly onto the lyophilised cake at high velocity can mechanically disrupt the peptide structure. Always inject slowly down the vial wall and allow passive dissolution rather than forcing it. Shaking rather than swirling similarly risks denaturation.
Disclaimer
This content is for educational and research purposes only. Retatrutide is not approved for human use. Dosage information is drawn from published clinical trial protocols and does not constitute medical advice.
Source Retatrutide for Research in the UK
UK researchers can source verified, independently HPLC-tested Retatrutide (≥99% purity, batch-specific COA) from Peptides Lab UK. For a complete overview of Retatrutide including mechanism, dosage protocols, and sourcing guidance, see our Retatrutide UK Complete Research Guide.
For research purposes only / not for human consumption.
